z-logo
open-access-imgOpen Access
Drug screening platform using human induced pluripotent stem cell‐derived atrial cardiomyocytes and optical mapping
Author(s) -
Gunawan Marvin G.,
Sangha Sarabjit S.,
Shafaattalab Sanam,
Lin Eric,
HeimsWaldron Danielle A.,
Bezzerides Vassilios J.,
Laksman Zachary,
Tibbits Glen F.
Publication year - 2021
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.19-0440
Subject(s) - induced pluripotent stem cell , transcriptome , retinoic acid , wnt signaling pathway , drug , pharmacology , drug discovery , medicine , chemistry , microbiology and biotechnology , signal transduction , bioinformatics , biology , gene expression , gene , embryonic stem cell , biochemistry
Current drug development efforts for the treatment of atrial fibrillation are hampered by the fact that many preclinical models have been unsuccessful in reproducing human cardiac physiology and its response to medications. In this study, we demonstrated an approach using human induced pluripotent stem cell‐derived atrial and ventricular cardiomyocytes (hiPSC‐aCMs and hiPSC‐vCMs, respectively) coupled with a sophisticated optical mapping system for drug screening of atrial‐selective compounds in vitro. We optimized differentiation of hiPSC‐aCMs by modulating the WNT and retinoid signaling pathways. Characterization of the transcriptome and proteome revealed that retinoic acid pushes the differentiation process into the atrial lineage and generated hiPSC‐aCMs. Functional characterization using optical mapping showed that hiPSC‐aCMs have shorter action potential durations and faster Ca 2+ handling dynamics compared with hiPSC‐vCMs. Furthermore, pharmacological investigation of hiPSC‐aCMs captured atrial‐selective effects by displaying greater sensitivity to atrial‐selective compounds 4‐aminopyridine, AVE0118, UCL1684, and vernakalant when compared with hiPSC‐vCMs. These results established that a model system incorporating hiPSC‐aCMs combined with optical mapping is well‐suited for preclinical drug screening of novel and targeted atrial selective compounds.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here